company background image

Penumbra NYSE:PEN Stock Report

Last Price


Market Cap







03 Jul, 2022


Company Financials +
PEN fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance0/6
Financial Health6/6

PEN Stock Overview

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally.

Penumbra Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Penumbra
Historical stock prices
Current Share PriceUS$125.70
52 Week HighUS$293.20
52 Week LowUS$114.87
1 Month Change-13.90%
3 Month Change-44.71%
1 Year Change-54.05%
3 Year Change-22.73%
5 Year Change41.32%
Change since IPO204.36%

Recent News & Updates

Jun 10

Penumbra: Multiple Downside Targets, Rescued By Long-Term Value Proposition

Fundamentally, Penumbra presents with the product economics and above-market sales trajectory to unlock long-term value. The stock has underperformed recently, yet, the value proposition in its operating segments remains. Despite this it remains exorbitantly valued, and we see multiple downside targets in place from our investigations. We've set a price target of $129 per share on a composite of inputs, rating PEN neutral as long-term holders of the stock.

Shareholder Returns

PENUS Medical EquipmentUS Market

Return vs Industry: PEN underperformed the US Medical Equipment industry which returned -24.7% over the past year.

Return vs Market: PEN underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is PEN's price volatile compared to industry and market?
PEN volatility
PEN Average Weekly Movement8.3%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: PEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PEN's weekly volatility (8%) has been stable over the past year.

About the Company

20043,800Adam Elsesser

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names.

Penumbra Fundamentals Summary

How do Penumbra's earnings and revenue compare to its market cap?
PEN fundamental statistics
Market CapUS$4.74b
Earnings (TTM)-US$6.47m
Revenue (TTM)US$782.28m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PEN income statement (TTM)
Cost of RevenueUS$290.82m
Gross ProfitUS$491.46m
Other ExpensesUS$497.94m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.17
Gross Margin62.82%
Net Profit Margin-0.83%
Debt/Equity Ratio0%

How did PEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is PEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PEN?

Other financial metrics that can be useful for relative valuation.

PEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6x
Enterprise Value/EBITDA-641.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PEN's PS Ratio compare to its peers?

PEN PS Ratio vs Peers
The above table shows the PS ratio for PEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.8x
OMCL Omnicell
GMED Globus Medical
IART Integra LifeSciences Holdings
IRTC iRhythm Technologies
PEN Penumbra

Price-To-Sales vs Peers: PEN is expensive based on its Price-To-Sales Ratio (6.1x) compared to the peer average (5.8x).

Price to Earnings Ratio vs Industry

How does PEN's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: PEN is expensive based on its Price-To-Sales Ratio (6.1x) compared to the US Medical Equipment industry average (3.7x)

Price to Sales Ratio vs Fair Ratio

What is PEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.1x
Fair PS Ratio5.2x

Price-To-Sales vs Fair Ratio: PEN is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (5.2x).

Share Price vs Fair Value

What is the Fair Price of PEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PEN ($125.7) is trading above our estimate of fair value ($86.13)

Significantly Below Fair Value: PEN is trading above our estimate of fair value.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PEN's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Penumbra forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score


Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: PEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PEN is expected to become profitable in the next 3 years.

Revenue vs Market: PEN's revenue (13.5% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: PEN's revenue (13.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PEN's Return on Equity is forecast to be low in 3 years time (6.7%).

Discover growth companies

Past Performance

How has Penumbra performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PEN is currently unprofitable.

Growing Profit Margin: PEN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PEN is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare PEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).

Return on Equity

High ROE: PEN has a negative Return on Equity (-0.86%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Penumbra's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PEN's short term assets ($690.3M) exceed its short term liabilities ($130.1M).

Long Term Liabilities: PEN's short term assets ($690.3M) exceed its long term liabilities ($212.2M).

Debt to Equity History and Analysis

Debt Level: PEN is debt free.

Reducing Debt: PEN has not had any debt for past 5 years.

Debt Coverage: PEN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PEN has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Penumbra current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PEN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PEN has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Adam Elsesser (60 yo)





Mr. Adam Elsesser serves as President at Penumbra, Inc. since May 2020. He Co-Founded Penumbra, Inc. in 2004 and has been its Chief Executive Officer since 2004. Mr. Elsesser has been the Chairman since Ja...

CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD497.79K) is below average for companies of similar size in the US market ($USD6.91M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: PEN's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: PEN's board of directors are considered experienced (6.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.

Top Shareholders

Company Information

Penumbra, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Penumbra, Inc.
  • Ticker: PEN
  • Exchange: NYSE
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$4.736b
  • Shares outstanding: 37.68m
  • Website:

Number of Employees


  • Penumbra, Inc.
  • One Penumbra Place
  • Alameda
  • California
  • 94502
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.